tovorafenib

Small moleculeapprovedOrphan Drug FDABreakthrough Therapy FDA

Approved

Apr 23, 2024

Clinical trial activity

7 trials · 4 clinical orgs · 1 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started May 2, 2022 (NCT07121829)

Timeline

2020s

  1. Sep 24, 2020

    Orphan Drug Designation

  2. Jan 1, 2022

    Day One Biopharmaceuticals, Inc. — Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

  4. Apr 23, 2024

    Day One Biopharmaceuticals, Inc. — Earliest FDA Approval

  5. Apr 23, 2024

    Day One Biopharmaceuticals, Inc. — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewAcceleratedBreakthroughApr 23, 2024

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06965114Phase 1/Phase 2 (Phase 2)Jun 27, 2026National Cancer Institute (NCI), Ohio State University
NCT07206849Phase 2Mar 1, 2026Ohio State University
NCT06381570Early Phase 1 (Phase 1)Mar 21, 2024University of Toronto
NCT05828069Phase 2Jan 2, 2024National Cancer Institute (NCI)
NCT05287295Phase 2Mar 8, 2023National Cancer Institute (NCI)
NCT07121829Phase 1May 2, 2022Day One Biopharmaceuticals, Inc.
NCT05760586N/ADay One Biopharmaceuticals, Inc.
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3312023
Day One Biopharmaceuticals, Inc.For profit2222022
Ohio State UniversityAcademic/Hospital2112026
University of TorontoAcademic/Hospital1112024
4 organizations
Page 1 / 1

Marketing (1)

OrganizationOrg typeRelationshipDate
Day One Biopharmaceuticals, Inc.For profitNDAApr 23, 2024